ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO489

Treatment Utilization and Disease Burden Associated with CKD Progression in Patients with Type 2 Diabetes

Session Information

Category: Diabetic Kidney Disease

  • 702 Diabetic Kidney Disease: Clinical


  • Amamoo, James J., Novo Nordisk Inc, Plainsboro, New Jersey, United States
  • Brady, Brenna L., Merative, Cambridge, Massachusetts, United States
  • Noone, Josh, Novo Nordisk Inc, Plainsboro, New Jersey, United States
  • Xie, Lin, Novo Nordisk Inc, Plainsboro, New Jersey, United States
  • Mehanna, Sherif, Novo Nordisk Inc, Plainsboro, New Jersey, United States
  • Varker, Helen V., Merative, Cambridge, Massachusetts, United States
  • Bakris, George L., University of Chicago, Chicago, Illinois, United States

Effective management of type 2 diabetes (T2D) is important for preventing/delaying complications, such as chronic kidney disease (CKD). This real-world, retrospective cohort study examined clinical characteristics and antidiabetic treatment utilization, particularly sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), in patients with CKD and T2D.


Data were obtained from the MerativeTM MarketScan® Explorys Claims-Electronic Health Record Database (January 1, 2016, to September 30, 2021). Patients were aged ≥18 years and had ≥2 estimated glomerular filtration rate (eGFR) values between 15 and 89 mL/min, indicating the same CKD stage within a 90-day period. The first eGFR value qualifying for inclusion was the index date, and patients were continuously enrolled for 6 months pre-index and 12 months post-index. Patients had diagnoses of CKD and T2D in the pre-index period. Treatment utilization was reported by CKD stages 2–3b; all analyses were descriptive.


: A total of 7,261 patients were included (mean ± SD age, 72.4 ± 10.6 years; 56.4% male). Patients had CKD stage 2 (28.0%), 3a (27.4%), 3b (29.5%), or 4 (15.1%). At pre-index, 4.2% and 7.8% of patients received SGLT2is and GLP-1RAs, respectively. At post-index, on average, 43.3% of patients across CKD stages 2–3b received metformin, 10.4% received GLP-1RAs, and 7.3% received SGLT2is; decreasing use of these agents was observed with CKD progression (Figure). In a subset of patients with poor glycemic control (glycated hemoglobin >7%; n=2,921), metformin, SGLT2i and GLP-1RA utilization was low; 18.2–30.1% received SGLT2is or GLP-1RAs (Figure).


Despite a large number of patients with comorbid CKD and T2D having poor glycemic control, SGLT2i and/or GLP-1RA utilization was low. Improved diabetes management is needed in this patient population.